Showing 571-580 of 5644 results for "".
New Therapy for Sjögren Disease on the Horizon
https://modernod.com/articles/significant-findings/new-therapy-for-sjogren-disease-on-the-horizon/45564/Significant Findings is MOD's weekly email newsletter for progressive-minded, full scope optometrists. Delivered to your inbox every Monday, Significant Findings offers fresh insights on the latest industry news, life anecdotes, current events related to the practice of optometry, and more—all cuNew MIGS Approach for Glaucoma Patients
https://modernod.com/articles/significant-findings/new-migs-approach-for-glaucoma-patients/39852/Significant Findings is MOD's weekly email newsletter for progressive-minded, full scope optometrists. Delivered to your inbox every Monday, Significant Findings offers fresh insights on the latest industry news, life anecdotes, current events related to the practice of optometry, and more—all cuThe Advent of Standalone MIGS and Opportunities for Patient Engagement
https://modernod.com/mod-issues/supplements-inserts/the-advent-of-standalone-migs-and-opportunities-for-patient-engagement/38543/Insights on patient identification, pearls for success, and perspective on the role of optometry in connecting patients with options for glaucoma management.A Special Farewell
https://modernod.com/editorial-series/significant-findings/a-special-farewell/51491/Significant Findings is MOD's weekly email newsletter for progressive-minded, full scope optometrists. Delivered to your inbox every Monday, Significant Findings offers fresh insights on the latest industry news, life anecdotes, current events related to the practice of optometry, and more—all cuThe OmniVu™ Lens System
https://modernod.com/articles/visionary-breakthroughs/the-omnivusupsup-lens-system/39820/Atia Vision designs a “no-compromise” PC-IOL.How to Tackle RCEs With Ease
https://modernod.com/articles/significant-findings/how-to-tackle-rces-with-ease/37854/Significant Findings is MOD's weekly email newsletter for progressive-minded, full scope optometrists. Delivered to your inbox every Monday, Significant Findings offers fresh insights on the latest industry news, life anecdotes, current events related to the practice of optometry, and more—all curatHearing and the Retina: A (Not-So) Surprising Link
https://modernod.com/articles/significant-findings/hearing-and-the-retina-a-not-so-surprising-link/37853/Significant Findings is MOD's weekly email newsletter for progressive-minded, full scope optometrists. Delivered to your inbox every Monday, Significant Findings offers fresh insights on the latest industry news, life anecdotes, current events related to the practice of optometry, and more—all curatReady to Embrace the Newest Dry Eye Drop?
https://modernod.com/articles/significant-findings/ready-to-embrace-the-newest-dry-eye-drop/37850/Significant Findings is MOD's weekly email newsletter for progressive-minded, full scope optometrists. Delivered to your inbox every Monday, Significant Findings offers fresh insights on the latest industry news, life anecdotes, current events related to the practice of optometry, and more—all curatSurvey Says …
https://modernod.com/articles/significant-findings/survey-says/37794/Significant Findings is MOD's weekly email newsletter for progressive-minded, full scope optometrists. Delivered to your inbox every Monday, Significant Findings offers fresh insights on the latest industry news, life anecdotes, current events related to the practice of optometry, and more—all curatThe Rundown on Vevye
https://modernod.com/videos/eye-care-insiders/the-rundown-on-vevye/37342/Joseph J. Allen, OD, FAAO, Dipl ABO, goes over what you need to know about the recently FDA-approved, nonpreserved cyclosporine ophthalmic solution 0.1% (Vevye, Novaliq) for treating the signs and symptoms of dry eye disease. He discusses what makes the drop unique compared with other cyclosporine p